Table 1.

Patient characteristics

	Patients (N = 56)	Control subjects (N = 29)
Age, yr	62 (53–68)	56 (49–58)
Males/females	2/54	3/26
Disease duration, yr	5 (7–24)
Current/prior/never smokers	7/21/28	2/27
Fulfilled AECG criteria for pSS	100 %
Anti-SS-A–positive	71 %
Anti-SS-B–positive	39 %
ANA-positive	73 %
RF-positive	50 %
Lip biopsy focus score ≥1	89 %
ESSDAI	7 (2–7)
ESSPRI	6 (5–8)
ESR, mm/h (n = 53)	17 (11–28)
IgG, g/L	13 (10–16)
C3, g/L	1.0 (0.9–1.2)
C4, g/L	0.18 (0.13–0.21)

AECG American-European Consensus Group, ANA anti-nuclear antibodies, anti-SS-A anti-Sjögren’s syndrome–related antigen A, anti-SS-B anti-Sjögren’s syndrome–related antigen B; C3 complement component 3, C4 complement component 4, ESR erythrocyte sedimentation rate, ESSDAI European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index, ESSPRI European League Against Rheumatism Sjögren’s Syndrome Patient-Reported Index, IgG immunoglobulin G, pSS primary Sjögren’s syndrome, RF rheumatoid factor

Values are given as median (interquartile range), number or percentage